Home / Business and Economy / Indian Pharma Shifts Gears: Beyond US Generics
Indian Pharma Shifts Gears: Beyond US Generics
7 Dec
Summary
- Indian pharma giants face flat US generic sales.
- Companies pivot to complex generics and specialty drugs.
- US market is crucial, supplying over 40% of generics.
Facing significant pricing pressures and stagnant growth in the United States generics market, major Indian pharmaceutical companies are initiating a strategic pivot. Firms such as Sun Pharma and Dr Reddy's Labs are increasingly focusing on high-value segments, including complex generics, specialty drugs, and innovative products. This strategic shift is a direct response to the challenging dynamics of the US generics landscape.
The US market, which accounts for a substantial portion of Indian pharmaceutical exports, has become increasingly volatile. Reports indicate double-digit dips in various generics segments, exacerbated by geopolitical realignments and rising operational costs. Consequently, companies are re-evaluating their strategies to ensure long-term sustainability and profitability in this crucial market.
In addition to focusing on differentiated products, Indian drugmakers are also exploring other avenues. These include improving manufacturing efficiencies and expanding into the contract development and manufacturing organization (CDMO) space. Companies like Cipla and Aurobindo Pharma are actively investing in new-age platforms and seeking to capture value in newer market segments to navigate the evolving global pharmaceutical environment.
